共 94 条
[1]
Perdrizet K(2019)The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer Curr Treat Options in Oncol 20 21-1616
[2]
Leighl NB(2016)Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis JAMA Oncol 2 1607-1756
[3]
Nishino M(2004)The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis Chest. 126 1750-1289
[4]
Giobbie-Hurder A(2002)Association of malignancy with diseases causing interstitial pulmonary changes Chest. 121 1278-867
[5]
Hatabu H(2002)Inflammation and cancer Nature. 420 860-68
[6]
Ramaiya NH(2019)Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON Lancet Respir Med 7 60-2082
[7]
Hodi F(2014)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2071-e9
[8]
Toh CK(2018)Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis Clin Lung Cancer. 19 e5-e68
[9]
Wong EH(2018)Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Am J Respir Crit Care Med 198 e44-e348
[10]
Lim WT(2018)safety and efficacy of pd-1/pd-l1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis Clin Lung Cancer 19 e335-290